| 1 |
35551149 | Evaluation of Inflammation and Atherogenesis Biomarkers Through 148 Weeks Post-Switch to Dolutegravir and Rilpivirine in SWORD-1/-2. | 2022 May 13 |
1 |
| 2 |
34120186 | Switching from boosted PIs to dolutegravir decreases soluble CD14 and adiponectin in high cardiovascular risk people living with HIV. | 2021 Aug 12 |
4 |
| 3 |
31478469 | Reduced soluble CD14 levels after switching from a dual regimen with lamivudine plus boosted protease inhibitors to lamivudine plus dolutegravir in virologically suppressed HIV-infected patients. | 2019 Sep 3 |
1 |